We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.23%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.99B
AUM Growth
-$1.5B
Cap. Flow
-$539M
Cap. Flow %
-10.81%
Top 10 Hldgs %
44.72%
Holding
159
New
13
Increased
22
Reduced
36
Closed
24

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$47.6M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$33.3M
3
NVRO
NEVRO CORP.
NVRO
+$32.7M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$32.1M
5
PEN icon
Penumbra
PEN
+$31.9M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$46.5M
4
KOD icon
Kodiak Sciences
KOD
+$44.1M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$37.1M

Sector Composition

Rank Sector Weight
1 Healthcare 81.81%
2 Financials 0.77%
3 Industrials 0.12%
4 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LABP
51
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$21.9M 0.44%
1,486,992
– –
ADMA icon
52
ADMA Biologics
ADMA
$2.02B
$21.8M 0.44%
11,933,387
– –
TARS icon
53
Tarsus Pharmaceuticals
TARS
$2.55B
$21.8M 0.44%
1,296,416
– –
AXNX
54
DELISTED
Axonics, Inc. Common Stock
AXNX
$21.4M 0.43%
+341,211
New +$18.4M
VERU icon
55
Veru
VERU
$35.5M
$21.1M 0.42%
436,200
-8,934
-2% -$485K
IMTX icon
56
Immatics
IMTX
$1.23B
$20M 0.4%
2,500,000
– –
QTNT
57
DELISTED
Quotient Limited Ordinary Shares
QTNT
$19.4M 0.39%
405,020
– –
AMLX icon
58
Amylyx Pharmaceuticals
AMLX
$2.19B
$18.9M 0.38%
+1,474,107
New +$33.3M
TMCI icon
59
Treace Medical Concepts
TMCI
$262M
$18.4M 0.37%
971,192
-8,994
-0.9% -$175K
KRON
60
DELISTED
Kronos Bio
KRON
$17.5M 0.35%
2,421,142
– –
SLDB icon
61
Solid Biosciences
SLDB
$792M
$16.1M 0.32%
894,170
– –
VRNA
62
DELISTED
Verona Pharma
VRNA
$15.2M 0.3%
3,044,303
+176,793
+6% +$1.03M
ISO
63
DELISTED
IsoPlexis Corporation Common Stock
ISO
$14M 0.28%
4,095,498
– –
CYPH
64
Cypherpunk Technologies Inc
CYPH
$64M
$13.9M 0.28%
795,145
-52,505
-6% -$1.12M
MGNX icon
65
MacroGenics
MGNX
$233M
$13.7M 0.28%
1,559,789
-105,454
-6% -$1.16M
LUNG icon
66
Pulmonx
LUNG
$52.8M
$13.3M 0.27%
537,779
-224,525
-29% -$5.8M
AORT icon
67
Artivion
AORT
$1.34B
$13.2M 0.26%
615,703
+289,385
+89% +$5.59M
LYRA
68
DELISTED
LYRA THERAPEUTICS INC
LYRA
$13M 0.26%
64,451
– –
HCAT icon
69
Health Catalyst
HCAT
$160M
$12.9M 0.26%
493,662
+39,658
+9% +$1.13M
RCUS icon
70
Arcus Biosciences
RCUS
$3.33B
$12.8M 0.26%
+405,000
New +$13.6M
RAIN
71
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$12.6M 0.25%
2,483,619
– –
SLGC
72
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$12M 0.24%
1,500,000
– –
ATNX
73
DELISTED
Athenex, Inc. Common Stock
ATNX
$11.2M 0.22%
676,623
– –
HLTH
74
DELISTED
Cue Health Inc. Common Stock
HLTH
$10.2M 0.2%
1,580,607
– –
ABSI icon
75
Absci
ABSI
$1.17B
$10M 0.2%
1,190,952
-220,824
-16% -$1.73M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Perceptive Advisors held 159 positions worth $4.99B, down 23% from $6.49B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $539M in Q1 2022, closing 24 positions and reducing 36 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in CinCor Pharma, Inc. Common Stock worth $40.7M.

  • Perceptive Advisors's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 2,319,117 shares worth $40.7M.
  • Perceptive Advisors added most to NEVRO CORP. in Q1 2022, an estimated $32.7M increase.
  • Perceptive Advisors's biggest Q1 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $92.4M.
  • Perceptive Advisors fully exited BioMarin Pharmaceuticals in Q1 2022, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $4.99B portfolio in Q1 2022.
  • Perceptive Advisors opened 13 new positions and closed 24 in Q1 2022.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $4.99B.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.